Patent ID: 7662782

Claim:
A method for treating an inflammatory disease condition comprising the administration of a pharmacologically effective amount of a compound of general formula (1): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are selected independently from H and methyl, and wherein R13, R14, R15 and R16 are selected independently from H and alkyl and wherein optionally one hydrogen in R13 and one hydrogen in R14 is exchanged for a bond between R13 and R14, and wherein optionally one hydrogen in R15 and one hydrogen in R16 is exchanged for a bond between R15 and R16, and wherein L1 and L2 are linkers which are independently selected from the group consisting of single bond, methyl and ethyl, and wherein R19 and R20 are selected independently from H and —CH 2 X, where X is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, heteroalkenyl, substituted heteroalkenyl, alkynyl, substituted alkynyl, heteroalkynyl, substituted heteroalkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, functional group Q, wherein Q is selected from the group consisting of amino, alkylamino, dialkylamino, arylamino, arylazido, heteroarylamino, heteroarylazido, hydroxyl, alkylhydroxy, fluorinated alkylhydroxy, cyano, carboxy, alkylcarboxy, arylcarboxy, halogen, nitro, hydroxylamino, acyl, fluorinated acyl, nitroso, sulfonyl, sulfinyl, thio, alkylthio and arylthio, and wherein R21 is selected independently from H, —CH(CH 3 ) 2 , and —CH 2 X, and wherein NT is selected from H, hydroxyl, alkyl, amino acid, amino acid analogue, polypeptide and functional group Q, and CT is selected from hydrogen, hydroxyl, alkyl, amino acid, amino acid analogue, polypeptide and functional group Q, and wherein each asymmetric center (*) is in R or S configuration, to a patient.